• 1
    Farley A, Wruble L, Humphries TJ. Rabeprazole vs. ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Am J Gastroenterol 2000; 95: 18949.
    Direct Link:
  • 2
    Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 1996; 69: 15974.
  • 3
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 4
    Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395407.
    Direct Link:
  • 5
    Ofman JJ, Yamashita BD, Siddique RM, Larson LR, Willian MK. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000; 6: 90516.
  • 6
    Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 13329.
    Direct Link:
  • 7
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 44554.
  • 8
    Sloan S. Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 and 7 days of treatment. Gut 2000; 47(Suppl. 3): A62(Abstract).
  • 9
    Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18: 234.
  • 10
    Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 30735.
  • 11
    Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277305.
  • 12
    Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997; 92(4 Suppl.): 17S21S.
  • 13
    Lambert R. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 65162.
  • 14
    Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 5967.
  • 15
    Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 64957.
  • 16
    Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 9838.
  • 17
    Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion – tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 10138.
  • 18
    Earnest DL, Robinson M. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution. Am J Gastroenterol 1999; 94(11 Suppl.): S1724.
  • 19
    Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 914.
  • 20
    Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193201.
  • 21
    Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 5761.
    Direct Link:
  • 22
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 143442.
    Direct Link:
  • 23
    Jones R, Bytzer P. Review article: acid suppression in the management of gastro-oesophageal reflux disease – an appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001; 15: 76572.
  • 24
    Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. The Multicentre Investigation Group. Aliment Pharmacol Ther 1995; 9: 2531.
  • 25
    Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001; 15: 26976.
  • 26
    Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1383401.
  • 27
    Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 34551.
  • 28
    Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 2237.
  • 29
    Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 46775.
  • 30
    Morgan DG, Burget DW, Howden CW, et al. Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis. Gastroenterology 1993; 104: A150(Abstract).
  • 31
    Breiter JR, Riff D, Humphries TJ. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Am J Gastroenterol 2000; 95: 93642.
    Direct Link:
  • 32
    Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 6615.
  • 33
    Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 46082.
  • 34
    Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40(Suppl. 2): 24S49S.
  • 35
    Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 2617.
  • 36
    Tunis SR, Sheinhait IA, Schmid CH, Bishop DJ, Ross SD. Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clin Ther 1997; 19: 74357.
  • 37
    Bonagura AF, Dabezies MA. Helicobacter pylori infection. The importance of eradication in patients with gastric disease. Postgrad Med 1996; 100: 1156,19–20,23–4.
  • 38
    National Institute of Health. Helicobacter pylori in peptic ulcer disease. NIH Concensus Statement 79 February 1994; 12: 122.
  • 39
    Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40: 5262.
  • 40
    Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 24370.
  • 41
    Joelsson B, Johnsson F. Heartburn – the acid test. Gut 1989; 30: 15235.
  • 42
    Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med 1999; 72: 18194.
  • 43
    Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 37.
  • 44
    Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 310.
  • 45
    Sachs G, Humphries TJ. Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interactions. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 12.
  • 46
    Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 117.
  • 47
    Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole and rabeprazole. Curr Gastroenterol Rep 2000; 2: 48293.
  • 48
    Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 5777.
  • 49
    Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002; 66: 27380.
  • 50
    Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 2243846.
  • 51
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 150714.
  • 52
    Gardner JD, Sloan S, Barth JA. Rabeprazole vs. omeprazole: onset, duration, and magnitude of gastric antisecretory effects. Gut 2000; 47: 43(Abstract).
  • 53
    Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 96378.
  • 54
    Röhss K, Wilder-Smith C, Claar-Nilsson C, Hasselgren G. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton-pump inhibitors. Gastroenterology 2001; 120(Suppl. 1): 2 (Abstract).
  • 55
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 56
    Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 102730.
  • 57
    Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66: 52834.
  • 58
    Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 32131.
  • 59
    Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 15639.
  • 60
    Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 273954.
  • 61
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 2736.
  • 62
    Kendall MJ. Review article: esomeprazole – the first proton pump inhibitor to be developed as an isomer. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 14.
  • 63
    Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, Carlsson E. Review article: esomeprazole – enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003; 17: 4818.
  • 64
    Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 7985.
  • 65
    Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 6272.
  • 66
    Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 1826.
  • 67
    Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 72542.
  • 68
    Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58: 15564.